anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The proposed study design will be a randomized, double-blind, placebo-controlled, parallel design to evaluate the effect of the supplement on cognitive function, well-being, mood, cognitive interferences, and inflammation. Participants will complete a series of psychological questionnaires, cognitive assessments, and venous blood draws.

Screening Visit (Visit 1) Upon arrival to the lab, participants will receive an informed consent document and will be required to give full consent before proceeding. Upon providing consent, participants will provide personal and emergency contact information before completing a health history form, exercise history form, and a physical activity questionnaire. Prior to this visit and each subsequent visit, participants will be required to observe an overnight fast (8-10 hours) of food or drink with calories including any foods or beverages that contain alcohol, caffeine, and nicotine. Participants will be instructed to be well-rested and to avoid exercise for 24 hours prior to each visit. Water intake will be encouraged during this time for appropriate hydration status. Participants will then have their height, body mass, resting heart rate, blood pressure, and urine specific gravity measured prior to completing their body composition assessment (only study visit 1) using a bioelectrical impedance analyzer (BIA). This study visit and all subsequent study visits will be scheduled between 0600 - 1000 hours. This study visit is estimated to take about 45 minutes to complete.

Visit 2-4 There is no required minimum time between Visit 1 and Visit 2. Visit 3 will occur 15 ± 3 days after Visit 2, 2 and Visit 4 will occur 28 ± 3 days after Visit 3. Participants will be required to follow identical pre-testing guidelines consisting of an overnight fast (8-10 hours) of food or drink with calories including any foods or beverages that contain alcohol, caffeine, and nicotine. Participants will be instructed to be well-rested and to avoid exercise for 24 hours prior to each visit. Water intake will be encouraged during this time for appropriate hydration status. Body mass, resting heart rate, and resting blood pressure will be measured. Female participants will take a urine pregnancy test to ensure they are not pregnant. Using standard phlebotomy approaches, approximately 21 mL of venous blood will be collected from a forearm vein. Participants will then complete the NIH Toolbox Cognitive Function Battery, NIH Toolbox Emotion Function Test, RAND SF-36 to assess well-being/mood, Stroop Color and Word test, Trail Making Test A and B, Finger tapping test, and the NIH Toolbox General Life Satisfaction score. After baseline testing, participants will be randomly assigned in a double-blind fashion to ingest on a daily basis for 6 weeks either a placebo or a dietary supplement. They will consume their supplement at the end of visits 2 and 3. Supplement compliance will be assessed through daily logging by the participant and checked by research team members calculating remaining amount of supplement during study visits.
Twenty chronic stroke survivors will be recruited for this study from an independent neuro-physiotherapy practice and community exercise programme.Gait analysis will be used to look at several gait parameters through the use of a three-dimensional visual analysis system based in our Biomechanics Lab at the University of Winchester. Participants will attend testing one testing session of approximately 1 hour. During this testing session functional measures and walking trials will be assessed. Participants will first be asked to complete a set of simple movements that will contribute towards Fugl Meyer questionnaire. Twenty eight reflective markers will then be attached to specified joints and segments of the body, such as the thigh, with double sided sticky tape to allow for data collection through the camera system to collect kinematic data. The belt mounted accelerometer (G-Walk) will be positioned around the waist over the L5 vertebrae. Participants will be asked to perform 6 walking trials of 10m to collect 3D kinematic and accelerometer gait data.
Outpatients aged over 50 years undergoing x-ray of the thoracic spine, lumbar spine, chest, pelvis, hand or knee will have their x-rays screened for low BMD by the software-as-a-medical device. If low BMD is identified by the software, a radiologist reviewing the x-ray may choose to incorporate this as an incidental finding in their report to the referring physician.
A method and an apparatus for continuously producing particles from an emulsion by supercritical fluid extraction. The emulsion includes a solute suspended or dissolved in the supercritical fluid soluble first phase. The supercritical fluid and the emulsion contact each other such that the first phase dissolves from the emulsion into the supercritical fluid and the solute precipitates to form a suspension in a non supercritical fluid soluble second phase of the emulsion. The supercritical fluid carries away the dissolved first phase. The solvent bearing supercritical fluid, together with the solute suspended in the second phase, is removed from an extraction chamber at a rate that is about the same as a rate that the emulsion and the supercritical fluid flow into the extraction chamber. Thus, a constant mass and pressure is maintained in the extraction chamber and the particles are produced continuously.
An antimicrobial agent comprising an extract of cells from an Asterostigma sp. plant of the Myrtaceae family for use in cosmetic and dermatological compositions, is new.  A new antimicrobial agent comprises an extract of cells from an Asterostigma sp. plant of the Myrtaceae family.  The extracts may be taken from any part of the plant, but preferably from the stem, bark, or leaves. Compositions preferably contain 0.05 - 20 % of active material, 0.1 - 5 % being especially preferred.
PURPOSE: A composition for relieving or preventing diabetes containing sun dried salt is provided to relieve insulin resistance and reduce blood sugar without side effects. CONSTITUTION: A food additive composition for relieving or preventing diabetes contains sun dried salt as an active ingredient. The sun dried salt contains 75-95 weight% of sodium chloride, 0.1-0.3 weight% of calcium, 0.15-0.45 weight% of potassium, and 0.4-2.0 weight% of magnesium. The sun dried salt additionally contains manganese(Mn), iron(Fe), copper(Cu), and strontium(Sr). The food additive composition contains 0.1-99 weight% of sun dried salt based on total weight. The food is beverage, gum, teat, vitamin complex or functional food.
<P>PROBLEM TO BE SOLVED: To obtain a composition for medicine quickly disintegrating in the oral cavity, which has excellent disintegration in the oral cavity and high hardness and is especially applicable also to a pharmacodynamic component unstable to water.  <P>SOLUTION: The composition for medicine comprises lactose and powder cellulose exhibits high hardness without prolonging a disintegration time in the oral cavity. The composition for medicine increases hardness without prolonging a disintegration time in the oral cavity by including further a disintegrator. The composition for medicine comprising magnesium aluminometasilicate and one or more kinds selected from silicic acid and silicates except magnesium aluminometasilicate exhibits high hardness without prolonging a disintegration time in the oral cavity. The composition for medicine is produced by a general industrial production method without requiring a specific pharmaceutical manufacturing technology.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The invention discloses a crocodile source aeromonas dactyli phoBR and kdpE gene deletion strain, a anaplerotic strain, a construction method and application thereof. The phoBR and kdpE gene deletion strain is obtained by deleting the phoBR and kdpE genes simultaneously on the basis of a wild strain of the aeromonas dacarbanae; the repayment strain is obtained by repayment expression of the kdpE gene on the basis of the gene deletion strain. Experiments prove that the genetic stability of the phoBR and kDPE gene deletion strain and the complementation strain thereof is improved. The Δphobr Δkdpe deleted strain grew indistinguishably but had increased sensitivity to antimicrobial peptides compared to the wild strain and the Δphobr deleted strain. The immunoprotection test shows that the immunoprotection rates of the delta phoBR delta kdpE deletion strain and the complementation strain thereof are 43.30% and 55.60%, respectively. The invention provides a technical means for the research of attenuated live vaccines of the crocodile dacarbazine disease.
Cohort A includes patients with microsatellite stable (MSS) colorectal cancer (CRC). Patients will receive a 14 day run-in of EDP1503 alone, following which they will be treated with a combination of EDP1503 and pembrolizumab.
Diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN) are challenging and often intractable complex medical conditions, with a substantial impact on the quality of life. Mirogabalin, a novel voltage-gated Ca2+ channel α2δ ligand, was approved for the indication of DPNP and PHN. However, the time course of effects has not yet been clarified.We aimed to establish pharmacodynamic and placebo effect models of mirogabalin and pregabalin in DPNP and PHN, and to quantitatively compare the efficacy characteristics (maximum efficacy, onset time, and other pharmacodynamic parameters) and safety of mirogabalin and pregabalin. Public databases were comprehensively searched for randomized placebo-controlled clinical trials. A model-based meta-analysis (MBMA) was developed to describe the time course of drug efficacy and placebo effects. Adverse events were compared using a fixed-effects meta-analysis. Sixteen studies including 5,147 participants were eligible for this study. The placebo effect was relatively high and gradually increased with time, and it required at least eight weeks to reach a plateau. The pharmacodynamic model revealed that the maximum pure efficacy for mirogabalin and pregabalin was approximately -7.85 % and -8.86 %, respectively; the efficacy of mirogabalin to relieve DPNP and PHN was not superior to that of pregabalin, and both drugs had similar safety. While the rate constant of the onset rate of pregabalin was approximately thrice as high as that of mirogabalin. In addition, the baseline level of pain was an important factor affecting pregabalin efficacy. These findings are helpful in evaluating the clinical extension value of mirogabalin. They suggest that the high placebo effect and the baseline level of pain should be considered when grouping patients in future research and development of voltage-gated Ca2+ channel neuroanalgesic.
PURPOSE: A composition for treating or preventing blood vessel diseases containing joiner extracts is provided to prevent activity of arginase and to increase produce of NO in blood vessel cells and main arteries. CONSTITUTION: A composition for treating or preventing blood vessel diseases contains fractions as main component. The fractions are obtained by the following steps: extracting the joiner by using alcohol; and extracting the crude extract by using ethyl acetate. The blood vessel disease is arteriosclerosis, hypertension, coronary artery disease, cerebrovascular disease, peripheral vascular disease or main artery disease. A health supplement for preventing and improving the blood vessel diseases includes fractions as main component. The fractions are obtained by the following steps: extracting the joiner by using alcohol; and extracting the crude extract by using ethyl acetate.
Period 1- Placebo controlled Period 2 - The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose (40, 60 or 80 mg). In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
Tibetan pigs are a unique swine strain adapted to the hypoxic environment of the plateau regions in China. The unique mechanisms underlying the adaption by Tibetan pigs, however, are still elusive. Only few studies have investigated hypoxia-associated molecular regulation in the lung tissues of animals living in the plateau region of China. Our previous study reported that ssc-miR-101-3p expression significantly differed in the lung tissues of Tibetan pigs at different altitudes, suggesting that ssc-miR-101-3p plays an important role in the adaptation of Tibetan pigs to high altitude. To understand the underlying molecular mechanism, in this study, the target genes of ssc-miR-101-3p and their functions were analyzed via various methods including qRT-PCR and GO and KEGG pathway enrichment analyses. The action of ssc-miR-101-3p was investigated by culturing alveolar type-II epithelial cells (ATII) of Tibetan pigs under hypoxic conditions and transfecting ATII cells with vectors overexpressing or inhibiting ssc-miR-101-3p. Overexpression of ssc-miR-101-3p significantly increased the proliferation of ATII cells and decreased the expression of inflammatory and apoptotic factors. The target genes of ssc-miR-101-3p were significantly enriched in FOXO and PI3K-AKT signaling pathways required to mitigate lung injury. Further, FOXO3 was identified as a direct target of ssc-miR-101-3p. Interestingly, ssc-miR-101-3p overexpression reversed the damaging effect of FOXO3 in the ATII cells. In conclusion, ssc-miR-101-3p targeting FOXO3 could inhibit hypoxia-induced apoptosis and inflammatory response in ATII cells of Tibetan pigs. These results provided new insights into the molecular mechanisms elucidating the response of lung tissues of Tibetan pigs to hypoxic stress.
Torsemide can cause sudden alterations of fluid and electrolyte balance which may precipitate hepatic coma in patients with hepatic disease with cirrhosis and ascites. In these patients, diuresis with torsemide is best initiated in the hospital.   
Diuretic treatment can cause or contribute to the development of hypovolemia, hypokalemia, metabolic alkalosis, hyponatremia or azotemia which can lead to new or worsening hepatic encephalopathy. Consider suspending or discontinuing torsemide [see Contraindications (4)].   
To prevent hypokalemia and metabolic alkalosis, use an aldosterone antagonist or potassium-sparing drug with torsemide in patients with hepatic disease.   
When given with aldosterone antagonists, torsemide also caused increases in sodium and fluid excretion in patients with edema or ascites due to hepatic cirrhosis. Urinary sodium excretion rate relative to the urinary excretion rate of torsemide is less in cirrhotic patients than in healthy subjects (possibly because of the hyperaldosteronism and resultant sodium retention that are characteristic of portal hypertension and ascites). However, because of the increased renal clearance of torsemide in patients with hepatic cirrhosis, these factors tend to balance each other, and the result is an overall natriuretic response that is similar to that seen in healthy subjects. Chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials.
A single dose of methylnaltrexone will be administered subcutaneously to eligible subjects based on weight at the study entry. Since we will include subjects at all stages of cancer management, administering this study drug is considered experimental. We will use the dose approved by FDA, i.e., 0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg.
<P>PROBLEM TO BE SOLVED: To provide a method for regulating the color of composite powder with which the color of the composite powder comprising a plurality of particles sticking to the surface of a thin-film piece can readily be regulated and to provide a method for estimating the color of the composite powder with which the color of the composite powder comprising the plurality of particles sticking to the surface of the thin-film piece can easily be estimated.  <P>SOLUTION: The method for regulating the color of the composite powder with which the color of the composite powder 10 comprising the plurality of particles 30 sticking to surface of the thin-film piece 20 is carried out as follows. The interval of the plurality of particles 30 on the surface of the thin-film piece 20 is regulated to thereby regulate the color of the composite powder 10. The method for estimating the color of the composite powder with which the color of the composite powder 10 comprising the plurality of particles 30 sticking to the surface of the thin-film piece 20 is carried out as follows. The color of the composite powder 10 is estimated from a reflection spectrum or a transmission spectrum of the composite powder 10 calculated for the interval of the plurality of particles 30 on the surface of the thin-film piece 20.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Term infants with respiratory failure and persistent pulmonary hypertension (PPHN) are among the most critically ill infants in the NICU, with significant mortality and morbidity reported even for infants with moderate disease. Currently, management is largely supportive, and includes oxygen, mechanical ventilation (conventional or high frequency ventilation), and exogenous surfactant therapy. Inhaled nitric oxide (iNO) is a pulmonary vasodilator that was approved for the treatment of hypoxic respiratory failure (HRF) and PPHN of the newborn in 1999 based on clinical trials showing a reduction in the need for rescue treatment with extracorporeal membrane oxygenation (ECMO).

One promising therapy to decrease pulmonary arterial pressure and improve oxygenation is sildenafil. Sildenafil is a cGMP-specific phosphodiesterase inhibitor that causes relatively selective pulmonary vasodilation. The use of intravenous (IV) sildenafil was recently FDA approved for use in adults in PPHN. A pilot trial studying dose response and pharmacokinetics in 36 term newborns with PPHN found that IV sildenafil was well tolerated and has the potential to induce marked improvements in oxygenation. The data from this pilot trial provided background to support the dosing regimen for this Phase II trial. We hypothesize that IV sildenafil will acutely reduce pulmonary artery pressure and improve oxygenation in near-term and term infants with PPHN, thus reducing the need for rescue therapy iNO and/or ECMO.
Participants received intravenous infusion of Herceptin® with docetaxel. The initial load dose of Herceptin® was 8mg/kg, followed by 6mg/kg every three weeks; The recommended dose of docetaxel is 75mg/m2, given once every 3 weeks for a treatment cycle of 3 weeks.
A novel mutant microorganism Streptococcus zooepidemi-cus HA-116 ATCC 39920, has been produced.  The microor-ganism produces large amounts of high molecular weight hyaluronic acid.   The invention provides a method of obtaining such microorganisms.            The invention also concerns a method of obtaining sodi-um hyaluronate which comprises growing with vigorous agitation a microorganism of the genus Streptococcus under  appropriate  conditions  in  a  suitable  nutrient medium containing a sugar component as a carbon source. The sugar component is present in a substantially con-stant concentration between 0.2 and 10 grams per liter. The  medium  has  a  substantially  constant  pH  between about 6.0 and 7.5 and includes a substantially constant magnesium ion concentration above 0.05 grams per liter. The sodium hyaluronate excreted into the medium by the organism is purified using methods involving precipa-tion,  redissolving and reprecipating the hyaluronate. Composition of sodium hyaluronate which are character-ized by an absence of pyrogenicity and skin irritation are obtained.
PURPOSE:A hairdye capable of dyeing the hair in various colors, consisting mainly of a cationic dye. CONSTITUTION:A hairdye consisting mainly of a cationic dye, e.g. C.I. Basic Blue 3 of the formula, having a bright color and improved light-fastness. The dye is used as follows: The hair is immersed in an aqueous hydrogen peroxide, pretreated, decolorized, and dyed with the hairdye solution in a bright color. The cationic dye has improved light-fastness compared with the conventional basic dyes, and is not toxic to the hair and skin.
The scheme belongs to the field of fluorescent nano material manufacturing, and relates to a preparation and use method of a targeted lipid drop washing-free fluorescent imaging nano probe. The probe is sensitive to the polarity of a solvent and has single-photon fluorescence and two-photon fluorescence characteristics. Can realize the rapid imaging of intracellular lipid drops without washing. Specifically, a solution formed by N, N-diethyl-p-phenylenediamine and absolute ethyl alcohol is subjected to solvothermal reaction for 12 hours at the temperature of 200 ℃ in a reaction kettle, dichloromethane and methanol are used as an eluent, and then the carbon dot fluorescent probe is obtained through rotary evaporation. The probe has high quantum yield, good stability and excellent biocompatibility; the fluorescent probe shows extremely high fluorescence intensity in a hydrophobic oily medium, and the fluorescence is quenched in an aqueous environment, so that specific imaging of lipid droplets can be realized. The nano probe prepared by the invention has the washing-free characteristic, simplifies the cell processing steps and can realize high contrast of imaging signals and background. Can be used for biological wide-field imaging, confocal imaging, super-resolution fluorescence imaging and the like.